Clinical Study of Rezvilutamide Combined With Docetaxel Chemotherapy in the Treatment of Abiraterone-Resistant Prostate Cancer

NCT07112209 · clinicaltrials.gov ↗

NA

Phase

ENROLLING_BY_INVITATION

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Pathological and Imaging Examinations Confirmed Metastatic Prostate Cancer

Interventions

COMBINATION_PRODUCT: Rezvilutamide combined with docetaxel

Sponsor

Zhujiang Hospital